Skip to main content
. Author manuscript; available in PMC: 2019 Mar 1.
Published in final edited form as: J Surg Oncol. 2017 Nov 22;117(4):634–643. doi: 10.1002/jso.24898

Figure 2.

Figure 2

A. Overall survival of 64 patients treated with systemic chemotherapy and HAI FUDR, stratified by prior chemotherapy exposure. Median survival was 38 months for all patients (n=64) (95% CI: 28.8–53.7). The median survival for chemo-naïve patients (n=21) was 76.6 months (95% CI: 38.6-NR) and 29.7 months (95% CI: 21.5–40.2) for previously treated patients (n=43) (p=0.022).

B. Progression-free survival of all patients stratified by prior chemotherapy exposure. Progression-free survival for all patients (n=64) was 13 months (95% CI: 9–16 months). Progression-free survival for chemotherapy-naïve patients was 19.7 months (95% CI: 13.1–23.4) and 10 months (95% CI: 6.2–14.3) for previously treated patients (p=0.020).